East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Nifedipine Extended-Release Tablets USP, 30 mg, 60mg and 90 mg. Aurobindo Pharma’s Nifedipine Extended-Release Tablets, 30 mg, 60mg, and 90 mg are an AB-rated generic equivalent to the reference listed drug (RLD), ADALAT® CC of Alvogen Group Holdings LLC.

Nifedipine Extended-Release Tablets are indicated for:

• The treatment of hypertension.